FIGURE 2.

C1 and its combination with sorafenib inhibited the growth of HCC in a dose-dependent manner. CVSA was performed in HCC cells after the treatment with C1 alone at different concentrations (4, 8 and 16 mg/ml) or in combination with sorafenib at different concentrations (3.45, 6.9 and 13.8 μM). CVSA readouts were performed (A) 24 h and (B) 48 h post-incubation. For a direct comparison to the standard therapy in the clinic, the sorafenib dose of 13.8 μM [human plasma concentration, as reported for the clinic (Fucile et al., 2015)], was used as a positive control.